Bioplus Acquisition Corp Stock Current Liabilities
BioPlus Acquisition Corp fundamentals help investors to digest information that contributes to BioPlus Acquisition's financial success or failures. It also enables traders to predict the movement of BioPlus Stock. The fundamental analysis module provides a way to measure BioPlus Acquisition's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioPlus Acquisition stock.
BioPlus |
BioPlus Acquisition Corp Company Current Liabilities Analysis
BioPlus Acquisition's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current BioPlus Acquisition Current Liabilities | 152.76 M |
Most of BioPlus Acquisition's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioPlus Acquisition Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, BioPlus Acquisition Corp has a Current Liabilities of 152.76 M. This is 93.94% lower than that of the Capital Markets sector and significantly higher than that of the Financials industry. The current liabilities for all United States stocks is 98.07% higher than that of the company.
Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
All Next | Launch Module |
BioPlus Fundamentals
Return On Asset | -0.0072 | |||
Current Valuation | 215.16 M | |||
Shares Outstanding | 19.37 M | |||
Shares Owned By Insiders | 48.69 % | |||
Shares Owned By Institutions | 51.31 % | |||
Number Of Shares Shorted | 1.64 K | |||
Price To Earning | (3.62) X | |||
EBITDA | (1.17 M) | |||
Net Income | 2 M | |||
Cash And Equivalents | 294.69 K | |||
Cash Per Share | 0.01 X | |||
Total Debt | 5 M | |||
Debt To Equity | 7.23 % | |||
Current Ratio | 2.96 X | |||
Book Value Per Share | (0.86) X | |||
Cash Flow From Operations | (691.47 K) | |||
Short Ratio | 0.03 X | |||
Earnings Per Share | 0.21 X | |||
Price To Earnings To Growth | (7.93) X | |||
Target Price | 20.0 | |||
Number Of Employees | 38 | |||
Beta | 0.14 | |||
Market Capitalization | 208.98 M | |||
Total Asset | 238.32 M | |||
Retained Earnings | (14.78 M) | |||
Working Capital | 21.89 K | |||
Current Asset | 183.69 M | |||
Current Liabilities | 152.76 M | |||
Z Score | 24.97 | |||
Net Asset | 238.32 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in BioPlus Stock
If you are still planning to invest in BioPlus Acquisition Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioPlus Acquisition's history and understand the potential risks before investing.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
CEOs Directory Screen CEOs from public companies around the world | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |